1. 441POT-1096: A first-in-class immunoactivating small molecule that targets the thioredoxin reductase/thioredoxin axis causes strong tumor growth inhibition by downregulating intratumoral tregs in a humanized TNBC-PDX model. (23rd October 2018) Authors: Orwar, O; Lowstedt, I; Andersson, K; Gannedahl, G; Willman, G; Davidsson, M; Stafford, W; Trkulja, C Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗